283 related articles for article (PubMed ID: 35605290)
1. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways.
Liu T; Jiang L; Xiang Z; Li J; Zhang Y; Xiang T; Wang W; Li X; Jia Y; Huang X; Lu X; Xu H; Wang X; Sheng J
Biomed Pharmacother; 2022 Jul; 151():113140. PubMed ID: 35605290
[TBL] [Abstract][Full Text] [Related]
2. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways.
Chen H; Fang C; Zhi X; Song S; Gu Y; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
J Cell Mol Med; 2020 Aug; 24(16):9067-9084. PubMed ID: 32604472
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways.
Zhi X; Fang C; Gu Y; Chen H; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
J Cell Mol Med; 2020 May; 24(9):5122-5134. PubMed ID: 32185887
[TBL] [Abstract][Full Text] [Related]
5. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
6. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
7. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
8. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
9. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
10. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
[TBL] [Abstract][Full Text] [Related]
11. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
12. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways.
Xu H; Jia Y; Li J; Huang X; Jiang L; Xiang T; Xie Y; Yang X; Liu T; Xiang Z; Sheng J
Biomed Pharmacother; 2022 May; 149():112902. PubMed ID: 35364377
[TBL] [Abstract][Full Text] [Related]
13. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
14. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
[TBL] [Abstract][Full Text] [Related]
15. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
16. Stauntonia hexaphylla (Lardizabalaceae) leaf methanol extract inhibits osteoclastogenesis and bone resorption activity via proteasome-mediated degradation of c-Fos protein and suppression of NFATc1 expression.
Cheon YH; Baek JM; Park SH; Ahn SJ; Lee MS; Oh J; Kim JY
BMC Complement Altern Med; 2015 Aug; 15():280. PubMed ID: 26271279
[TBL] [Abstract][Full Text] [Related]
17. KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.
Liou SF; Hsu JH; Lin IL; Ho ML; Hsu PC; Chen LW; Chen IJ; Yeh JL
PLoS One; 2013; 8(7):e69468. PubMed ID: 23936022
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
19. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation.
Chiou WF; Huang YL; Liu YW
PLoS One; 2014; 9(2):e89159. PubMed ID: 24558484
[TBL] [Abstract][Full Text] [Related]
20. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]